tbuckley/cabot-search huggingface dataset:
Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design
Authors: Sean P. Collins, Phillip D. Levy, Jane L. Holl, Javed Butler, Yosef Khan, Tiffany L. Israel, Gregg C. Fonarow, Jacqueline Alikhaani, Eric Sarno, Alison Cook, Clyde W. Yancy
Journal: JAMA Cardiology (2017)

Patient centeredness is a concept that is increasingly being viewed as essential for clinical research. A core principle involves a comprehensive assessment and integration of patient and caregiver perspectives into trial design. Importantly, this involves more than just soliciting feedback. Patients and caregivers are now considered vital members of the study team, even serving as coinvestigators who may help to conceive, plan, and develop the study; continue to direct the day-to-day conduct of the study; and fully participate in the dissemination of the study results. The Patient-Centered Outcomes Research Institute offers substantial funding to support this approach, but getting started, particularly at institutions that lack a robust community engagement infrastructure, can be daunting. In this Special Communication, successful methods that have been used by researchers to engage patients, caregivers, and the broader health care community in the research process are outlined, and examples of currently funded studies that have fully engaged key stakeholders are described. Although trials are designed to assess efficacy and effectiveness and inform future implementation and dissemination, this Special Communication emphasizes methods to ensure trial results are relevant to and understood by the individuals and groups that they are intended to impact. Critical next steps in this new research approach are also discussed. In doing so, this will inspire future cardiovascular research that evaluates not only traditional end points, such as mortality and readmission, but also emphasizes true patient-centered outcomes, including quality of life, knowledge and satisfaction, caregiver burden, time tradeoffs, and out-of-pocket costs.
FDA Approval Summary: Sonidegib—Letter
Authors: Bishal Gyawali, Yuichi Ando
Journal: Clinical Cancer Research (2017)

We read with interest the FDA approval summary for sonidegib, an inhibitor of the Hedgehog signaling pathway and smoothened receptors, for patients with locally advanced basal cell carcinoma ([1][1]). On the basis of the results from the randomized BOLT trial ([2][2]), sonidegib was approved by the
Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice
Authors: A. Gobert, A. Jaeger, L. Taillade, N. Osman, D. Lassoued, C. Mateescu, P. Maingon, P. Tilleul, J-P. Spano, A. Bellanger
Journal: Annals of Oncology (2017)
PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer
Authors: Y. Narita, E. Sasaki, Y. Yatabe, K. Kato, H. Okano, S. Mitani, K. Honda, T. Masuishi, H. Taniguchi, S. Kadowaki, T. Ura, M. Ando, M. Tajika, S. Ito, K. Muro
Journal: Annals of Oncology (2017)
The Complexity of Subjective Cognitive Decline
Authors: Rik Ossenkoppele, William J. Jagust
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
Authors: M. Retz, J. Bedke, E. Herrmann, M-O. Grimm, U. Zimmermann, L. Müller, C. Leiber, D. Teber, M. Wirth, C. Bolenz, R. van Alphen, M. De Santis, A. Beeker, M. Frank, J.E. Gschwend
Journal: Annals of Oncology (2017)
Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors
Authors: N. Yamamoto, K. Muro, H. Ishii, T. Kato, T. Tsushima, M. Takenoyama, S. Oizumi, T. Kawakami, T. Doi
Journal: Annals of Oncology (2017)
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
Authors: William J Sandborn, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Klopocka, Jochen Klaus, Walter Reinisch, Xavier Hébuterne, Dong-Il Park, Stefan Schreiber, Satyaprakash Nayak, Alaa Ahmad, Anindita Banerjee, Lisa S Brown, Fabio Cataldi, Kenneth J Gorelick, John B Cheng, Mina Hassan-Zahraee, Robert Clare, Geert R D’Haens
Journal: Gut (2017)

This phase II, randomised, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule (MAdCAM) to selectively reduce lymphocyte homing to the intestinal tract, in patients with moderate-to-severe Crohn's disease (CD).Eligible adults were aged 18-75 years, with active moderate-to-severe CD (Crohn's Disease Activity Index (CDAI) 220-450), a history of failure or intolerance to antitumour necrosis factor and/or immunosuppressive agents, high-sensitivity C reactive protein >3.0 mg/L and ulcers on colonoscopy. Patients were randomised to PF-00547659 22.5 mg, 75 mg or 225 mg or placebo. The primary endpoint was CDAI 70-point decrease from baseline (CDAI-70) at week 8 or 12.In all, 265 patients were eligible for study entry. Although CDAI-70 response was not significantly different with placebo versus PF-00547659 treatment at weeks 8 or 12, remission rate was greater in patients with higher baseline C reactive protein (>5 mg/L vs >18.8 mg/L, respectively). Soluble MAdCAM decreased significantly from baseline to week 2 in a dose-related manner and remained low during the study in PF-00547659-treated patients. Circulating β7+ CD4+ central memory T-lymphocytes increased at weeks 8 and 12 with PF-00547659 treatment. No safety signal was seen.Clinical endpoint differences between PF-00547659 and placebo did not reach statistical significance in patients with moderate-to-severe CD. PF-00547659 was pharmacologically active, as shown by a sustained dose-related decrease in soluble MAdCAM and a dose-related increase in circulating β7+ central memory T cells.NCT01276509; Results.
Real-world overall survival in advanced melanoma from the IMAGE study.
Authors: Mark R. Middleton, Philippa Corrie, Stéphane Dalle, Michal Lotem, Ruth Board, Ana Maria Arance Fernández, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Carmen Loquai, Toby Talbot, Rudolf Herbst, Katharina C. Kaehler, SRIVIDYA KOTAPATI, Trong Kim Le, Jane Brokaw, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2016)

9531 Background: IMAGE (ipilimumab: management of advanced melanoma in real practice) is an ongoing multinational, prospective, observational study that assesses the treatment of advanced (unresectable or metastatic) melanoma (MEL) in a real-world setting. Although there are adequate accumulating overall survival (OS) data from randomized controlled trials for patients (pts) diagnosed with advanced MEL, OS data from robust real-world studies are not available. As a result, the IMAGE study evaluated OS in pts with advanced MEL who received ipilimumab (IPI) and non-IPI therapies. Methods: IMAGE included adult pts who were not participating in a clinical trial and received IPI or other non-IPI therapies. Pts were followed from study enrollment (April 2012) to data extraction (November 27, 2015). Data were collected by electronic case report forms. Results: Of the 1,371 pts included in this study, 84% (n = 1,152) received IPI therapy and 16% (n = 219) did not receive IPI at any time during the study period. At study entry, 60% of pts were male, median age was 64 years, mean follow-up was 8 months, 79% were on second or subsequent line of systemic therapy, 97% had distant metastases, and among 94% of pts (n = 1,285) with BRAF testing, 42% (n = 540) expressed the mutation. In non-IPI pts, the most common systemic MEL therapies were dacarbazine (17%), fotemustine (17%), vemurafenib (15%), dabrafenib (13%), and pembrolizumab (9%). Median OS during the study period (study entry to death or censoring at discontinuation, study completion, or data extraction date) was 11 months (95% CI: 10–13) for IPI pts and 9 months (95% CI: 6–11) for non-IPI pts. The OS probability at year 1 was 48% (standard error: 2%) for IPI pts and 41% (standard error: 4%) for non-IPI pts. Conclusions: Although these are interim data and further follow-up analyses will be needed to confirm these findings, the OS results from IMAGE are consistent with those observed in advanced MEL clinical trials showing improved OS with IPI.
Bichat recommandations sur la prise en charge clinique des patients présentant une maladie du charbon lors d'un acte de bioterrorisme
Authors: P Bossi, A Tegnell, A Baka, F van Loock, J Hendriks, A Werner, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

Bacillus anthracis responsable de la maladie du charbon, doit etre considere comme l’un des agents infectieux les plus a meme a etre utilises comme arme biologique. Les differents cas de maladie du charbon observes a la suite d’envois de couriers
Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation
Authors: Juliette Soret, Bruno Cassinat, Sylvie Chevret, Christine Dosquet, Stephane Giraudier, Emmanuelle Verger, Nabih Maslah, Nathalie Parquet, Christine Chomienne, Jean-Jacques Kiladjian
Journal: Blood (2016)
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
Authors: S. Bracarda, L. Galli, M. Maruzzo, G. Lo Re, S. Buti, A. Favaretto, F.D. Costanzo, C. Sacco, M. Merlano, C. Mucciarini, E. Zafarana, S. Romito, A. Maestri, C. Giannitto Giorgio, M.T. Ionta, D. Turci, U. De Giorgi, G. Procopio, E. Cortesi, C. Porta
Journal: Annals of Oncology (2017)
Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways
Authors: A. Herreros Pomares, S. Calabuig Fariñas, E. Escorihuela, H. Amado, R. Guijarro, S. Gallach Garcia, A. Navarro, E. Jantus-Lewintre, C. Camps Herrero
Journal: Annals of Oncology (2017)
Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002
Authors: A. Daud, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F.S. Hodi, J. Schachter, J. Sosman, A.C. Pavlick, R. Gonzalez, C.U. Blank, L. Cranmer, S.J. O’Day, A.K. Salama, K. Margolin, J. Yang, B. Homet Moreno, N. Ibrahim, A. Ribas
Journal: Annals of Oncology (2017)
Clinical Significance of Right Ventricular Longitudinal Function Parameters After Aortic Valve Replacement
Authors: Augustin Coisne, Thomas Modine, François Outteryck, Stéphanie Mouton, Rosario Pilato, Hélène Ridon, Marjorie Richardson, Anju Duva-Pentiah, Anne-Laure Madika, Guillaume Ledieu, Bertrand Boutie, Mathilde Jacquelinet, Sandro Ninni, Cedric Klein, Staniel Ortmans, Alexis Classeau, Mohamad Koussa, Georges Fayad, Jean-Louis Edmé, Patrizio Lancellotti, David Montaigne
Journal: JACC. Cardiovascular imaging (2017)
A phase II study of sequential Irinotecan plus cisplatin (IP) and octretide LAR as first-line treatment of metastatic or inoperable poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).
Authors: Jie Li, Ming Lu, Zhihao Lu, Jun Zhou, Xicheng Wang, Jian Li, Yan Li, Xiaotian Zhang, Jing Gao, Lin Shen
Journal: Journal of Clinical Oncology (2014)

e15156 Background: Chemotherapy was the main therapeutic option for NEC. Somatostatin analogs (SSA) were well known to be effective in GEP-NET. We conducted a prospective, phase II study to evaluate the efficacy and safety of sequential IP therapy and Octreotide LAR in patients with metastatic or inoperable GEP-NEC. Methods: Patient with histologically confirmed NEC (Ki 67>20%) were treated with the IP regimen: Irinotacen 180mg/m2 on d1, and Cisplatin 50mg/m2 on d1, repeat cycle every 2 weeks for six cycles. After chemotherapy, patients without disease progression received Octreotide LAR as maintenance treatment. The primary endpoint was overall progression free survival (PFS) and respective PFS in the two treatment steps. The secondary endpoint was disease control rate (DCR), overall survival (OS) and safety. Results: From 2011 to 2013, 40 patients were enrolled. The median number of treatment cycles was 3 (range 1-6). Fifteen patients completed six cycles chemotherapy and 12 patients stopped early because of toxicity. Overall RR was 45%(18/40) and DCR was 67.5%(27/40). The overall mPFS was 5.6 (95%CI: 3.2, 7.9) months. Twenty-seven patients were confirmed without progression after chemotherapy, 13 patients received Octreotide LAR therapy. Median PFS after chemotherapy in patients treated with Octreotide LAR was 3.1 (95%CI: 2.0, 4.3) months vs 4.1 (95%CI: 2.1, 6.1) months in patients not received Octreotide LAR therapy, p=0.908. 13/40 had died at this analysis with ongoing mOS of 12.6 months. The most common G3/4 toxicities were Neutropenia (50%), Leukopenia (35%), Nausea/Vomiting (7.5%), Diarrhea (5%), Anorexia (5%). No chemotherapy related death occurred in this study. Conclusions: The IP regimen, as first-line chemotherapy, was an active treatment option for patients with metastatic or inoperable GEP-NEC. However, dose adjustment of both drugs was necessary because of toxicity. The application of Octreotide LAR as maintenance treatment failed to improve PFS according to study results. Clinical trial information: NCT01480986. Clinical trial information: NCT01480986.
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data
Authors: G.A. Bjarnason, J. Knox, C.K. Kollmannsberger, D. Soulieres, D.S. Ernst, P. Zalewski, C.M. Canil, E. Winquist, S.J. Hotte, S.A. North, D.Y.C. Heng, R.J. Macfarlane, P.M. Venner, A. Kapoor, A.R. Hansen, P. Czaykowski, B. Boyd, L. Wang, N.S. Basappa
Journal: Annals of Oncology (2017)
Early detection of circulating tumor DNA for the assessment of resistance or relapse to neoadjuvant chemotherapy in breast cancer patients
Authors: E. Isnaldi, L. Ferrando, A. Garuti, G. Cirmena, P. Franceschelli, P. Fregatti, A. Garlaschi, D. Friendman, A. Ballestrero, G. Zoppoli
Journal: Annals of Oncology (2017)
Syphilis surveillance and trends of the syphilis epidemic in Germany since the mid-90s
Authors: U Marcus, V Bremer, O Hamouda
Journal: Eurosurveillance (2004)

Recent surveillance reports from Europe and the United States show an increase in syphilis cases. Accurate epidemiological information about the distribution of syphilis is important for targeting screening and intervention programmes. The German syphilis notification system changed in 2001 from physician to laboratory-based reporting, which is complemented by a newly introduced sexually transmitted infection (STI) sentinel system. After reaching an all time low during the 1990s, syphilis notifications have increased significantly since 2001, coinciding with the introduction of the new reporting system. However, the increased reported incidence is reflecting a true rise in the number of cases and is not predominantly determined by more underreporting through the previous reporting system. The increase reflects syphilis outbreaks among men who have sex with men (MSM). The first of these outbreaks was observed in Hamburg in 1997. In 2003, incidence in men was ten times higher than in women. An estimated 75% of syphilis cases are currently diagnosed among MSM. A high proportion (according to sentinel data, up to 50%) of MSM diagnosed with syphilis are HIV positive. The continuously high number of syphilis cases diagnosed among heterosexuals in Germany in recent years compared with other western European countries may reflect the higher population movement between Germany and syphilis high incidence regions in south-east and eastern Europe.
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
Authors: S.P.P. Gampenrieder, G. Rinnerthaler, H. Hackl, M. Steiner, C. Monzo Fuentes, C. Hufnagl, C. Hauser-Kronberger, A. Egle, R. Greil
Journal: Annals of Oncology (2017)
Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy
Authors: K. Tryfonidis, C. Poncet, L. Slaets, G. Viale, F. de Snoo, K. Aalders, L. Van 't Veer, E. Rutgers, M. Piccart, J. Bogaerts, F. Cardoso
Journal: Annals of Oncology (2017)
Pathology
Authors: W. Marshall
Journal: BMJ (1998)

“Pathology? No thanks! Stuck away in a lab all day, the stink of formaldehyde, other doctors' dead patients…“ Sadly, this is a common image, even among doctors. Another popular misconception, reinforced on television, is that all pathologists are forensic pathologists, dealing with suspicious deaths. But pathology is not about crime or death; it is about understanding disease and disease processes.

Forensic pathology is a small subspecialty of histopathology. Pathology's other main disciplines are chemical pathology, microbiology, haematology, and immunology. All pathologists spend some of their time working in the lab, but they do a lot more besides. Many pathologists now have direct responsibility for the care of patients, bringing the intellectual satisfaction of investigation and diagnosis with the practical satisfaction of patient care.

Also known as clinical biochemistry, a major role of this discipline is the provision of an analytical service for measuring a wide variety of analytese”electrolytes,” enzymes, proteins, hormones, vitamins, drugs, etcefor diagnostic and management purposes. Much of this analytical work is performed by biomedical scientists using automated analysers, but the chemical pathologist is the director of the service, responsible for ensuring its quality and appropriateness and providing guidance on the selection of investigations and interpretation of their results.

### Attractions and drawbacks of pathology

#### Attractions

#### Drawbacks

Chemical pathologists may perform some of the tests themselves, particularly dynamic endocrine tests. They consult on the investigation and management of patients with metabolic disorders, and, increasingly, have direct …
Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.
Authors: I Brian Greenwell, Ashley Darnell Staton, Michael J Lee, Jeffrey M. Switchenko, Joseph J. Maly, Kristie A. Blum, Natalie Sophia Grover, Stephanie Mathews, Steven I. Park, Max J Gordon, Alexey Valeryevich Danilov, Christopher Flowers, Jonathon Brett Cohen
Journal: Journal of Clinical Oncology (2016)

7565 Background: Complex karyotype (CK) has been associated with inferior outcomes in mantle cell lymphoma (MCL) and other hematologic malignancies, including, but has only been evaluated in small MCL cohorts. We conducted a multi-center assessment of the impact of a CK on progression-free (PFS) and overall survival (OS) in patients with previously untreated MCL. Methods: Untreated patients (pts) with MCL from 4 academic centers diagnosed between 1993 and 2015 were included. Pts with 3 or more chromosomal abnormalities were defined as having CK. We described differences in clinical variables of interest between pts with and without CK and used the Kaplan-Meier method to estimate OS and PFS for each group. Multiple variable (MV) Cox regression analyses including MIPI components and demographics were performed to identify independent predictors of PFS and OS. Results: Of 248 pts, 89% had stage IV disease, and 19% had a CK (n = 48). The most common induction regimens included: R-HCVAD(n = 45), BR(n = 28), methotrexate with augmented R-CHOP(n = 36), and R-CHOP (n = 36). Median PFS was 2.2 years for pts with CK, and 4.5 years for pts without CK. Median OS was 4.5 years with CK, and 11.6 years without CK. Among 94 (37%) patients undergoing autologous stem cell transplant (ASCT) in 1st remission, the median PFS was 3.6 years for CK and 6.7 years without CK (p < 0.001) while the median OS was 5.1 years for CK and 8.6 years without CK (p = 0.023). Among pts who did not undergo ASCT in first remission (n = 107), the median PFS was 1.4 years for CK and 3.8 years for without CK (p = 0.002) and the median OS was 3.2 years for CK and not reached for without CK (p < 0.001). In MV analysis, CK (hazard ratio [HR] = 2.51) and ASCT in 1st remission (HR = 0.44) were the only predictors of PFS, and CK (HR = 2.36) was the only independent predictor for OS. Conclusions: CK is independently associated with inferior OS and PFS, regardless of the receipt of ASCT. Future studies should prospectively evaluate CK to aid in identifying high-risk patients for alternative therapies which may improve long-term outcomes.
GW28-e0698 Telmisartan with amlodipine versus lisinopril with amlodipine on home blood pressure variability in patients with metabolic syndrome
Authors: Alyavi Anis Lutfullayevich, Alyavi Baxrom Anisxonovich, Uzokov Jamol Kamilovich, Azizov Shuxrat Ismatovich, Kayumov Nodir Ulugbekovich
Journal: Journal of the American College of Cardiology (2017)
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients
Authors: N. Nabieva, S. Kellner, T. Fehm, L. Häberle, J. de Waal, M. Rezai, B. Baier, G. Baake, H.-C. Kolberg, M. Guggenberger, M. Warm, N. Harbeck, R. Wuerstlein, J.-U. Deuker, P. Dall, B. Richter, G. Wachsmann, C. Brucker, J.W. Siebers, N. Fersis, T. Kuhn, C. Wolf, H.-W. Vollert, G.-P. Breitbach, W. Janni, R. Landthaler, A. Kohls, D. Rezek, T. Noesselt, G. Fischer, S. Henschen, T. Praetz, V. Heyl, T. Kühn, T. Krauss, C. Thomssen, A. Hohn, H. Tesch, C. Mundhenke, A. Hein, C. Rauh, C.M. Bayer, A. Jacob, K. Schmidt, E. Belleville, S.Y. Brucker, S. Kümmel, M.W. Beckmann, D. Wallwiener, P. Hadji, P.A. Fasching
Journal: Annals of Oncology (2017)
RX-3117, an oral hypomethylating agent to treat advanced solid tumors (st): Interim results from an ongoing phase 2a study in advanced urothelial cancer
Authors: M.C. Maia, S.K. Pal, S.T. Tagawa, V. Chung, J. Picus, S. Gupta, J. Poore, C. Peterson, E. Benaim
Journal: Annals of Oncology (2017)
Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case–control study and recommendations
Authors: H Maguire, S Brailsford, J Carless, M Yates, L Altass, S Yates, S Anaraki, A Charlett, S Lozewicz, M Lipman, G Bothamley
Journal: Eurosurveillance (2011)

Binary file ES_Abstracts_Final_ECDC.txt matches
POLE mutations and MSI were positive predictive factors for progression free survival in endometrial cancer patients at the risk of recurrence
Authors: A. Nyuya, J. Haraga, T. Nagasaka, K. Nakamura, T. Haruma, T. Nishida, K. Yasui, T. Fujiwara, A. Goel, H. Masuyama
Journal: Annals of Oncology (2017)